Preventing Contamination with Preservatives - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Preventing Contamination with Preservatives
If a product does not have its own antimicrobial properties, then a preservative must be used to ensure microbiological safety. Greg Snowdon from RSSL offers his advice on using preservatives.

Pharmaceutical Technology Europe


Q How can a preservative's efficacy be shown?

Efficacy of an antimicrobial preservation is commonly performed at two points in the product development process. The first point is during the formulation stage, where developers are looking at a range of the most promising preparations. The preservative is incorporated and the test carried out. This should narrow down the field of potentials, or confirm those that have already been chosen.

The second point is during stability storage, usually at the beginning and end of storage. A middle time point, however, can also be beneficial to catch failures earlier in the cycle. Testing during stability storage is perhaps the most important testing point because it highlights potential efficacy problems with the preservative. For example, it will show if the preservative degrades over time, which would require a higher starting level. Even if the preservative doesn't degrade, it may not remain biologically available. The test will show this. Different temperatures or humidity may cause the preservative to fall out of suspension or solution. The efficacy test will show any microbiological problems, the physical and chemical tests that are carried out concurrently can often then tell you why.

The actual testing method is very straightforward. The preparation is contaminated with a high level of chosen microorganisms and, at specific time points, the remaining level of each of the organisms is determined.

The Pharmacopoeias prescribe a set of test organisms that cover the basic types: Staphylococcus aureus for the Gram positives, Pseudomonas aeruginosa for the Gram negatives, Candida albicans for the yeasts and Aspergillus brasiliensis (formerly Aspergillus niger) for the moulds. The US Pharmacopeia includes Escherichia coli in its standard challenge organism list, while the European Pharmacopoeia reserves E.coli for use in oral preparations.

There is also the option of including organisms of interest, such as Zygosaccharomyces rouxii (anosmotolerant spoilage yeast) for high-sugar preparations, environmental isolates (either from a known contamination issue, or one that keeps appearing when you check the manufacturing area).

There is currently no requirement to test against antibiotic-resistant "super bugs". Although these organisms have evolved a method for protecting themselves from a variety of antibiotics, most preservative systems work along different pathways and so will have the same effect against both normal and 'super' varieties.

The Pharmacopoeias have a list of the minimum required efficacy based on the product type, be it oral, topical or parenteral. The requirement is expressed as a Log10 reduction from the microbiological challenge level after a defined period of contact. Depending on the preparation type the fungi may only be required not to increase in numbers from the previous value. In addition, there are tests against a variety of organisms to ensure as wide an effect as possible. If the preparation doesn't meet these requirements, it's back to the formulation stage!

A common pitfall at this point is not realising that the Pharmacopoeias are not harmonised on efficacy testing. There may be different requirements and testing to one may not cover the others. A few things can be considered in the formulation stage that should help reduce the proportion of failures in the preservative efficacy test, and they all revolve around the premise of knowing your preservative:

  • At what level is the preservative expected to be effective? For example, benzoic acid is effective against E.coli at 120 ppm, but requires 2000 ppm to be effective against A.brasiliensis.
  • How soluble is the preservative in the product? The preservative may be efficacious at 1%, but if the solubility in the preparation is only 0.1% then it probably won't work.
  • Is the preservative stable? Or is it likely to degrade with time, or temperature or by reaction with the preparation? All of these will reduce or negate its efficacy.

Some of above can be estimated in advance, but in the end the only way to know is to try.

Greg Snowdon is a microbiology scientist at RSSL.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here